Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey N Weitzel

Showing results (81-90 of 220) with videos related to

Pageof 22
Sort By:
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, Mark Robson, Judy E Garber, et al.
Patient Education and Counseling|June 18, 2010
Health literacy, numeracy, and interpretation of graphical breast cancer risk estimatesSandra M Brown, Julie O Culver, Kathryn E Osann, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM William Audeh, James Carmichael, Richard T Penson, et al.
Journal of Genetic Counseling|May 26, 2022
Cross-sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessmentBita Nehoray, Thomas P Slavin, Can-Lan Sun, et al.
JCO Global Oncology|June 28, 2021
Development and Pilot Implementation of the Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) Intervention in MexicoKathleen R Blazer, Yanin Chavarri-Guerra, Cynthia Villarreal Garza, et al.
Breast Cancer Research and Treatment|April 7, 2021
Multigene assessment of genetic risk for women for two or more breast cancersJeffrey N Weitzel, John Kidd, Ryan Bernhisel, et al.
Breast Cancer Research and Treatment|May 19, 2018
Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos, Jacek Gronwald, Henry T Lynch, et al.
European Journal of Human Genetics : EJHG|July 6, 2012
Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populationsYael Laitman, Bing-Jian Feng, Itay M Zamir, et al.
JCO Oncology Practice|April 10, 2025
Educational Video as an Alternative to Pretest In-Person Genetic Counseling in Candidates for Cancer Genetic Testing: A Randomized Controlled Noninferiority TrialYanin Chavarri-Guerra, Mayte Cruz-Zermeño, Cesar Alcacio-Vazquez, et al.
Journal of the Endocrine Society|June 25, 2021
A Novel, Likely Pathogenic <i>MAX</i> Germline Variant in a Patient With Unilateral PheochromocytomaCésar Ernesto Lam-Chung, Larissa López Rodríguez, Jazmín Arteaga Vázquez, et al.
Pageof 22

Showing results (81-90 of 220) with videos related to

Sort By:
Pageof 22
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, Mark Robson, Judy E Garber, et al.
Patient Education and Counseling|June 18, 2010
Health literacy, numeracy, and interpretation of graphical breast cancer risk estimatesSandra M Brown, Julie O Culver, Kathryn E Osann, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM William Audeh, James Carmichael, Richard T Penson, et al.
Journal of Genetic Counseling|May 26, 2022
Cross-sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessmentBita Nehoray, Thomas P Slavin, Can-Lan Sun, et al.
JCO Global Oncology|June 28, 2021
Development and Pilot Implementation of the Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) Intervention in MexicoKathleen R Blazer, Yanin Chavarri-Guerra, Cynthia Villarreal Garza, et al.
Breast Cancer Research and Treatment|April 7, 2021
Multigene assessment of genetic risk for women for two or more breast cancersJeffrey N Weitzel, John Kidd, Ryan Bernhisel, et al.
Breast Cancer Research and Treatment|May 19, 2018
Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos, Jacek Gronwald, Henry T Lynch, et al.
European Journal of Human Genetics : EJHG|July 6, 2012
Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populationsYael Laitman, Bing-Jian Feng, Itay M Zamir, et al.
JCO Oncology Practice|April 10, 2025
Educational Video as an Alternative to Pretest In-Person Genetic Counseling in Candidates for Cancer Genetic Testing: A Randomized Controlled Noninferiority TrialYanin Chavarri-Guerra, Mayte Cruz-Zermeño, Cesar Alcacio-Vazquez, et al.
Journal of the Endocrine Society|June 25, 2021
A Novel, Likely Pathogenic <i>MAX</i> Germline Variant in a Patient With Unilateral PheochromocytomaCésar Ernesto Lam-Chung, Larissa López Rodríguez, Jazmín Arteaga Vázquez, et al.
Pageof 22